Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.34 |
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15322998 | 0.88 | EPHX1 (0.50) | EPHX1DPP8DPP4DPP7BCHE | |
| Trifluoroacetic Acid SCHEMBL3275665 | 0.79 | CYP3A4 (0.37) | DPP8DPP4DPP7DRD2DRD1 | |
| Trifluoroacetic Acid SCHEMBL30408711 | 0.79 | CYP3A4 (0.37) | DPP8DPP4DPP7DRD2DRD1 | |
| Trifluoroacetic Acid SCHEMBL30407660 | 0.79 | CYP3A4 (0.37) | DPP8DPP4DPP7DRD2DRD1 | |
| Trifluoroacetic Acid SCHEMBL7259177 | 0.78 | DPP4 (0.40) | DPP8DPP4DPP7DRD2DRD1 | |
| SCHEMBL21296532 | 0.77 | EPHX1 (0.43) | EPHX1BCHE | |
| SCHEMBL15800379 | 0.77 | EPHX1 (0.43) | EPHX1BCHE | |
| SCHEMBL23081228 | 0.76 | ALDH1A1 (0.36) | CHRNB2CHRNA4 | |
| SCHEMBL16759353 | 0.76 | ALDH1A1 (0.36) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL2146244 | 0.76 | EPHX1 (0.42) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4138824-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | Anovia Biosciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20050009843-A1 | Medicine for inhibiting drug elimination pump | TRINE PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
| EP-1389463-A1 | MEDICINE FOR INHIBITING DRUG ELIMINATION PUMP | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009843-A1 | Medicine for inhibiting drug elimination pump | ABCB11, ATP6AP1, HRH2 | EPHX1 1332/4885DPP8 2778/4885DPP4 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.